IMO the wording in that presentation is deliberately equivocal and I implore shareholders to ask Mr Rogers to be a lot clearer in explaining to the market where PRR actually stands with CVAC and the US regulatory process. Whilst I'm not saying this is mis-information it certainly is far from best practice.
A phase II study should NOT be referred to as a pivotal study.
Considering how many mum and dad investors with little understanding of the US regulatory process I fear that there are going to be a lot of dissapointed people whom have been led to believe that PRR and specifically CVAC is a lot further progressed than it actually is.
The substantial funds required for a phase III pivotal trial in the US IMO will only ever be forthcoming after PRR has generated far more robust phase II data.
The capital markets or a trade partner (who will fund a phase III study) will require the phase II data as a pre-requisite and this is yet to be delivered.
- Forums
- ASX - By Stock
- IMM
- worst corporate governance on the asx
worst corporate governance on the asx, page-77
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
30.0¢ |
Change
-0.020(6.25%) |
Mkt cap ! $435.7M |
Open | High | Low | Value | Volume |
31.5¢ | 31.5¢ | 29.5¢ | $2.355M | 7.796M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 128197 | 29.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.0¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 128197 | 0.295 |
19 | 601843 | 0.290 |
15 | 178898 | 0.285 |
23 | 1297758 | 0.280 |
6 | 183301 | 0.275 |
Price($) | Vol. | No. |
---|---|---|
0.300 | 100000 | 1 |
0.305 | 126168 | 4 |
0.310 | 157018 | 5 |
0.315 | 28000 | 2 |
0.320 | 82625 | 5 |
Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |